FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499012016> ?p ?o ?g. }

• W2499012016 endingPage "1944" @default.
• W2499012016 startingPage "1935" @default.
• W2499012016 abstract "Background This was a proof‐of‐concept study to evaluate the efficacy of LY 2940094, a nociceptin/orphanin FQ peptide receptor antagonist, in reducing alcohol consumption in actively alcohol‐drinking patients with alcohol dependence. Methods Eighty‐eight patients, 21 to 66 years of age, diagnosed with alcohol dependence, reporting 3 to 6 heavy drinking days per week, were randomized (1:1) to 8 weeks of treatment with once‐daily oral placebo ( N = 44) or 40 mg/d of LY 2940094 ( N = 44). The primary efficacy analysis was the change from baseline in number of drinks per day ( NDD ) utilizing mixed‐model repeated measures comparing LY 2940094 and placebo in Month 2 of the 8‐week double‐blind treatment period. The probability that the difference relative to placebo in NDD was ≤0 at endpoint was calculated, and a probability ≥80% was considered to be evidence that LY 2940094 was associated with the reduction in NDD . Results After 8 weeks of treatment, reduction in mean NDD did not differ between LY 2940094 versus placebo (−1.4 vs. −1.5, respectively, 44% probability of greater reduction relative to placebo), but there was a greater reduction in the mean percentage of heavy drinking days in a month with LY 2940094 versus placebo (−24.5 vs. −15.7%, respectively, 93% probability of a greater reduction relative to placebo), and an increase in the mean percentage of abstinent days in a month compared to placebo (9.1 vs. 1.9%, respectively, 91% probability of a greater increase relative to placebo). Patients who were treated with LY 2940094 showed decreased plasma levels of gamma‐glutamyl transferase with probabilities ≥98% for greater reduction compared with placebo at Weeks 1, 4, 6, and 8. Treatment‐emergent adverse events in ≥5% of patients treated with LY 2940094 included insomnia, vomiting, and anxiety. There were no serious adverse events or significant changes in laboratory assessments or vital signs with LY 2940094. Conclusions Although not reducing the NDD , LY 2940094, compared to placebo, did reduce heavy drinking days and increased abstinence days in patients with alcohol dependence." @default.
• W2499012016 created "2016-08-23" @default.
• W2499012016 creator A5002528675 @default.
• W2499012016 creator A5009906241 @default.
• W2499012016 creator A5016763533 @default.
• W2499012016 creator A5029375830 @default.
• W2499012016 creator A5037353908 @default.
• W2499012016 creator A5037912275 @default.
• W2499012016 creator A5066572032 @default.
• W2499012016 creator A5067708666 @default.
• W2499012016 creator A5070339215 @default.
• W2499012016 creator A5075420771 @default.
• W2499012016 date "2016-07-20" @default.
• W2499012016 modified "2023-10-16" @default.
• W2499012016 title "Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence" @default.
• W2499012016 cites W1475474724 @default.
• W2499012016 cites W1839921965 @default.
• W2499012016 cites W1910982087 @default.
• W2499012016 cites W1967138211 @default.
• W2499012016 cites W1981100187 @default.
• W2499012016 cites W1987888141 @default.
• W2499012016 cites W2002153331 @default.
• W2499012016 cites W2003975632 @default.
• W2499012016 cites W2016562510 @default.
• W2499012016 cites W2040421480 @default.
• W2499012016 cites W2048199491 @default.
• W2499012016 cites W2051762113 @default.
• W2499012016 cites W2055873049 @default.
• W2499012016 cites W2066624199 @default.
• W2499012016 cites W2071553034 @default.
• W2499012016 cites W2097950056 @default.
• W2499012016 cites W2100886729 @default.
• W2499012016 cites W2108740579 @default.
• W2499012016 cites W2120377396 @default.
• W2499012016 cites W2122807925 @default.
• W2499012016 cites W2123282949 @default.
• W2499012016 cites W2124216937 @default.
• W2499012016 cites W2125065061 @default.
• W2499012016 cites W2130325363 @default.
• W2499012016 cites W2139060090 @default.
• W2499012016 cites W2143015721 @default.
• W2499012016 cites W2148083007 @default.
• W2499012016 cites W2152189927 @default.
• W2499012016 cites W2159950826 @default.
• W2499012016 cites W2162363996 @default.
• W2499012016 cites W2166281097 @default.
• W2499012016 cites W2172151487 @default.
• W2499012016 cites W2305498579 @default.
• W2499012016 cites W2312239788 @default.
• W2499012016 cites W2338517189 @default.
• W2499012016 cites W2470287449 @default.
• W2499012016 cites W4233780223 @default.
• W2499012016 cites W4236025940 @default.
• W2499012016 cites W78479983 @default.
• W2499012016 doi "https://doi.org/10.1111/acer.13147" @default.
• W2499012016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27435979" @default.
• W2499012016 hasPublicationYear "2016" @default.
• W2499012016 type Work @default.
• W2499012016 sameAs 2499012016 @default.
• W2499012016 citedByCount "31" @default.
• W2499012016 countsByYear W24990120162016 @default.
• W2499012016 countsByYear W24990120162017 @default.
• W2499012016 countsByYear W24990120162018 @default.
• W2499012016 countsByYear W24990120162019 @default.
• W2499012016 countsByYear W24990120162020 @default.
• W2499012016 countsByYear W24990120162021 @default.
• W2499012016 countsByYear W24990120162022 @default.
• W2499012016 countsByYear W24990120162023 @default.
• W2499012016 crossrefType "journal-article" @default.
• W2499012016 hasAuthorship W2499012016A5002528675 @default.
• W2499012016 hasAuthorship W2499012016A5009906241 @default.
• W2499012016 hasAuthorship W2499012016A5016763533 @default.
• W2499012016 hasAuthorship W2499012016A5029375830 @default.
• W2499012016 hasAuthorship W2499012016A5037353908 @default.
• W2499012016 hasAuthorship W2499012016A5037912275 @default.
• W2499012016 hasAuthorship W2499012016A5066572032 @default.
• W2499012016 hasAuthorship W2499012016A5067708666 @default.
• W2499012016 hasAuthorship W2499012016A5070339215 @default.
• W2499012016 hasAuthorship W2499012016A5075420771 @default.
• W2499012016 hasConcept C125439840 @default.
• W2499012016 hasConcept C126322002 @default.
• W2499012016 hasConcept C142724271 @default.
• W2499012016 hasConcept C168563851 @default.
• W2499012016 hasConcept C170493617 @default.
• W2499012016 hasConcept C185592680 @default.
• W2499012016 hasConcept C203092338 @default.
• W2499012016 hasConcept C204787440 @default.
• W2499012016 hasConcept C27081682 @default.
• W2499012016 hasConcept C2776885963 @default.
• W2499012016 hasConcept C2779436514 @default.
• W2499012016 hasConcept C2781063702 @default.
• W2499012016 hasConcept C2781066024 @default.
• W2499012016 hasConcept C42219234 @default.
• W2499012016 hasConcept C55493867 @default.
• W2499012016 hasConcept C71924100 @default.
• W2499012016 hasConcept C88016717 @default.
• W2499012016 hasConceptScore W2499012016C125439840 @default.
• W2499012016 hasConceptScore W2499012016C126322002 @default.

• next